Litcius/Paper detail

Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population

Liang Zeng, Lili Xiao, Wenjuan Jiang, Haiyan Yang, Dandan Hu, Xia Chen, Yizhi Li, Chunhua Zhou, Yi Xiong, Li Liu, Dehua Liao, Rui Guan, Kunyan Li, Jing Wang, Yongchang Zhang, Nong Yang, Aaron S. Mansfield

2020Lung Cancer32 citationsDOI

Topics & Concepts

MedicineBevacizumabT790MInternal medicineCohortPropensity score matchingOncologyLung cancerPopulationCancerEpidermal growth factor receptorGefitinibChemotherapyEnvironmental healthLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population | Litcius